Clinical trials for Anal cancer

87 currently recruiting clinical trials
Phase 1 / Phase 2 Breast cancer Lung cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer #NCT04104776 #2023-508002-20-00
Urothelial carcinoma Locally Advanced Metastatic ARID1A 1 2 3 or more
Systemic Treatment-Naive
Centre Hospitalier Universitaire - Site Hôtel Dieu (Nantes), Gustave Roussy (Villejuif), ICANS - Institut de cancérologie Strasbourg Europe (Strasbourg), Centre Hospitalier Universitaire de Nantes (Nantes), Institut Bergonié (Bordeaux) (and 2 more...)
Constellation Pharmaceutique
Phase 1 / Phase 2 Colon cancer Rectal cancer Anal cancer Pancreas cancer #NCT06162221
Locally Advanced Metastatic KRAS G12C 1 2 3 or more
Systemic Treatment-Naive Systemic Treatment-Naive
Hôpital Foch (Suresnes), Centre François Baclesse (Caen ), IUCT Oncopôle (Toulouse), Gustave Roussy (Villejuif), Hôpital Louis Pradel (Bron ) (and 9 more...)
Revolution Medicines, Inc.
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06220864 #2025-520557-36-00
Expansion de dose pour les tumeurs solides avec des métastases cérébrales
Locally Advanced Metastatic Metastatic Castration-resistant 1 2 3 or more
Systemic Treatment-Naive
Institut de Cancérologie de l'Ouest - Site de Saint-Herblain (Saint-Herblain)
Synnovation Therapeutics, Inc.
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06220864 #2025-520557-36-00
Escalade et extension de dose monothérapie et escalde de dose combinaison
Locally Advanced Metastatic Metastatic Castration-resistant 1 2 3 or more
Systemic Treatment-Naive
Institut de Cancérologie de l'Ouest - Site de Saint-Herblain (Saint-Herblain)
Synnovation Therapeutics, Inc.
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT05382559 #2022-501590-39-00
ASP3082 Cohortes monothérapie
Locally Advanced Metastatic Metastatic Castration-resistant KRAS G12D 1 2 3 or more
Systemic Treatment-Naive
Centre Léon Bérard (Lyon), Hôpital Lyon Sud - Hospices Civils de Lyon (Pierre-Bénite), Institut Bergonié (Bordeaux), Centre Hospitalier Universitaire de Grenoble (La Tronche), Gustave Roussy (Villejuif)
Astellas Pharma Développement mondial, Inc.
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT05382559 #2022-501590-39-00
Cohorte combinaison ASP3082 + Cetuximab
Locally Advanced Metastatic Metastatic Castration-resistant KRAS non G12C 1 2 3 or more
Systemic Treatment-Naive
Institut Bergonié (Bordeaux), Gustave Roussy (Villejuif), Centre Hospitalier Universitaire de Grenoble (La Tronche), Hôpital Lyon Sud - Hospices Civils de Lyon (Pierre-Bénite), Centre Léon Bérard (Lyon)
Astellas Pharma Développement mondial, Inc.
Phase 1 Breast cancer Lung cancer Prostate cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT07156136
Locally Advanced Metastatic Metastatic Castration-resistant Other mutation 1 2 3 or more
Systemic Treatment-Naive
Centre Hospitalier Universitaire de Toulouse (Toulouse), Gustave Roussy (Villejuif), Centre Léon Bérard (Lyon)
Immunocore Ltée
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Lymphoma Ovarian / Fallopian tubes / Peritoneum cancer #NCT06514651
Metastatic 1 2 3 or more
IUCT Oncopôle (Toulouse)
MabQuest SA
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06431594 #2024-513860-25-00
Escalade de dose
Locally Advanced Metastatic Metastatic Castration-resistant 1 2 3 or more
Systemic Treatment-Naive
Institut de Cancérologie de l'Ouest - Site de Saint-Herblain (Saint-Herblain), Centre Léon Bérard (Lyon), Gustave Roussy (Villejuif)
GlaxoSmithKline
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06561685
Phase 1a Escalade de dose
Locally Advanced Metastatic Metastatic Castration-resistant Other mutation 1 2 3 or more
Systemic Treatment-Naive
Institut Curie - Paris (Paris)
Eli Lilly et compagnie